Plaats nieuw bericht   Plaats Reactie
Share | |
Vorige onderwerp Printervriendelijke versie Log in om je privé berichten te bekijken Volgende onderwerp
Auteur Bericht
Onderwerp: Hoop op werkend Medicijn voor ME/CVS  BerichtGeplaatst: 26 Apr 2018 - 11:03

Geregistreerd op: 18 05 2015
Berichten: 61

Status: Offline
MILL VALLEY, Calif., April 24, 2018 /PRNewswire/ -- The Synergy Trial, one of the largest treatment intervention clinical trials in Chronic Fatigue Syndrome (CFS) to date, tested a combination treatment consisting of a currently available stimulant drug co-administered with a micronutrient formula known to broadly support mitochondrial function. This treatment is referred to as "KPAX002".

Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, highly variable neurodegenerative disease affecting over 2 million Americans. The disease is characterized by new-onset fatigue persisting for at least 6 months that is severe enough to produce a substantial decrease in activity. ME/CFS currently has no FDA-approved treatment.

The Synergy Trial was a double-blinded, placebo-controlled study that enrolled 128 participants with moderate to severe ME/CFS. The trial was conducted at four research sites in the United States including, the ME/CFS Initiative at Stanford University, California, the Bateman Horne Center in Salt Lake City, Utah, The Sue Levine Medical Clinic in NYC, and the Dept. of Clinical Immunology, Nova Southeastern University, Ft. Lauderdale, Florida. The trial was funded by K-PAX Pharmaceuticals and the lead investigator was Stanford University Professor, Dr. Jose Montoya (see bio below).

The study's results identified that KPAX002 was most effective in subjects with more severe ME/CFS symptoms and those with both fatigue and pain; two key subgroups that responded best to the treatment. ME/CFS patients in these groups had more than double the level of improvement after treatment with KPAX002 as patients taking the placebo. KPAX002 was also found to be safe and well tolerated.

(.....) kopierecht

Volledig artikel

 Bekijk gebruikers profiel Stuur privé bericht  
Reageer met quote Naar boven
Onderwerp:   BerichtGeplaatst: 26 Apr 2018 - 23:02
Site Admin
Site Admin

Geregistreerd op: 13 10 2005
Berichten: 2871
Woonplaats: Onder de zon
Kritisch tegengeluid Frank Twisk:

Teleurstellende resultaten KPAX002 trial

Hoop doet leven!
 Bekijk gebruikers profiel Stuur privé bericht Bekijk de homepage  
Reageer met quote Naar boven
Berichten van afgelopen:     
Ga naar:  
Tijden zijn in GMT - 12 uur
Plaats nieuw bericht   Plaats Reactie
Vorige onderwerp Printervriendelijke versie Log in om je privé berichten te bekijken Volgende onderwerp
Powered by Zafenio